Market Survey on Age Related Molecular Degeneration Market Covering Sales Outlook, Up-to-date Key Trends, Market Size and Forecast, Per Capita Expenditure, Company Share, Brand Share, Regulations, Reimbursement Scenario, Epidemiology, Procedure Numbers, and Pipeline Assessment
An In-depth Market Insights of Age Related Molecular Degeneration Market including Eylea, Lucentis, and Beovu Covering 30+ Countries like United States, United Kingdom, Germany, France, Norway, Sweden, Saudi Arabia, United Arab Emirates, Japan, Korea, Australia, New Zealand, and Others
Age-Related Molecular Degeneration Market Snapshot (2023 to 2033)
The global age-related molecular degeneration market is currently valued at US$ 11.28 Million in 2023 and is anticipated to expand at a CAGR of 7%. Owing to the technological advances in healthcare the market is likely to propel to US$ 22.19 Million by 2033.
The expansion and development of the healthcare sector and the rise in the prevalence of age-related molecular degeneration are likely todrive the growth of the age-related molecular degeneration marketin the forecast period.
Report Attribute
Details
Expected Market Value (2023)
US$11.28 Million
Projected Forecast Value (2033)
US$ 22.19 Million
Global Growth Rate (2023 to 2033)
7% CAGR
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Age-Related Molecular Degeneration Market Revenue Analysis 2018 to 2022 vs. Future Outlook 2023 to 2033
The age-related molecular degeneration market is expected to gain market growth in the forecast period of 2023 to 2033. Latest market analysis by FMI the market is to grow at a CAGR of 7% in the above-mentioned forecast period.
Older people are at greater risk of eye disorders, and hence, globally, the increasing aged population is further expected to generate traction for the age-related molecular degeneration market over the forecast period of2023 to2033. Moreover, manufacturers are generating awareness about eye health through age-specific advertisements and awareness drives.
AMD is characterized by progressive degeneration of the macula, the central part of the retina, leading to central vision loss. AMD can be classified as early, intermediate, or late based on its clinical features, including drusen, pigmentation abnormalities, atrophy of the retinal pigment epithelium (RPE), and exudative choroidal neovascularization (CNV).
Molecular degeneration has seen a substantial rise in incidence over the past years and this has led to an increase in eye treatment demand, and this trend is expected to be prevalent over the coming years as well. The global age-related molecular degeneration market rose at a CAGR of 6.4% from 2018 to 2022.
What Market Trends Are Influencing the Age-Related Molecular Degeneration Market?
The rising Growth of the Older Age Population and The Increasing Number of AMD Patients Will Contribute to Market Growth
Age-related macular degeneration disease is happening to the increasing geriatric population, and the numerous cases of the condition are raising the demand for treatment.
The rising geriatric population is one of the major factors driving the age-related molecular degeneration industry potential. For instance, according to WHO by 2030, 1 in 6 people in the world will be aged 60 years or over. At this time the share of the population aged 60 years and over will increase from 1 billion in 2020 to 1.4 billion.
According to a research article published in 2020, around 170 million people are affected by AMD around the world. In the US, the prevalence of AMD cases is about 11 million. These data show that there is an immense need for medicines for the treatment of the condition, which eventually prompts the expansion of the age-related macular degeneration market size during the forecast period.
Increased Spending On Research & Development Drives the Age-Related Molecular Degeneration Market
Constant research & development are evident in the healthcare industry and this is common for eye disease and diagnosis as well. Wet AMD infections have been a major cause of concern as they account for a significant amount of total age-related molecular degeneration in the world.
The increasing number of individuals with retinal disorders is directly proportional to market growth. Thus, the increasing burden of such disorders is driving the demand for macular degeneration treatment which is further contributing to market growth.
Also, the increasing research and development (R&D) investments and rising approvals for new drugs are other major factors for the market growth.
Find your sweet spots for generating winning opportunities in this market.
Which Factors Are Restraining the Growth in Age-Related Molecular Degeneration Market?
Lack of Awareness Regarding the Disorder May Hamper the Growth
Despite a positive growth trajectory, the global age-related molecular degeneration market is facing various challenges that are likely to pose a threat to its growth during the forecast period.
Some of these factors are a lack of awareness about molecular degeneration and poor availability of certain products across emerging economies. Also, the ignorance of the effects of infections and the lack of inclination towards taking proper treatments may hamper the market growth.
Country-Wise Insights
What Makes the USA an Attractive Market for Age-Related Molecular Degeneration?
Booming Eyecare Products Market and Rising Investments in Research and Development Driving Growth in the USA Market
The USA is estimated to account for over 50.6% of the North American age-related molecular degeneration market in 2022. The growth of the market in the region is attributed to the increasing prevalence of AMD.
The rising prevalence of dry eye syndrome, and the presence of leading pharmaceutical manufacturers, are some of the factors driving demand in the USA market.
For instance, according to the Centre for Disease Control, the number of AMD cases in older Americans is projected to nearly double from 48 million to 88 million in 2050.
An increase in government initiatives, the number of research partnerships, and the presence of the key market players, coupled with recent product launches, are anticipated to boost the growth of the market in the North American region
For instance,inApril 2019 - Novartis announced that the US Food and Drug Administration (FDA) accepted the company's Biologics License Application (BLA) for brolucizumab (RTH258) for the treatment of wet age-related macular degeneration (AMD), also known as neovascular AMD, or nAMD.
Why is the Age-Related Molecular Degeneration Market in Europe Expected to Be Highly Opportunistic?
Increase in Significant Research and Development Investments in Healthcare to Boost the Market Growth
The Europe age-related molecular degeneration market is expected to rise at a CAGR of 6.7% from 2023 to 2033. Europe is the second-largest shareholder in the market, mainly due to the growing political support and favorable reimbursement regulations for medical services.
Increasing ophthalmological disorders in the region to boost the market growth in Europe. The large presence of pharmaceutical companies and growing aging populations are driving the demand in Germany.
For instance, in February 2020 - Novartis today announced the European Commission (EC) has approved Beovu® (brolucizumab) injection for the treatment of wet age-related macular degeneration (AMD). Beovu is the first EC-approved anti-VEGF treatment to demonstrate superior resolution of retinal fluid (IRF/SRF), a key marker of disease activity, versus aflibercept (secondary endpoints)1,5. Beovu also offers the ability to start eligible wet AMD patients on a three-month dosing interval immediately after the loading phase.
Which Factors Are Supporting Growth of the Age-Related Molecular Degeneration Market in the Asia Pacific?
Rapid development in pharmaceuticals to drive the market growth in Asia Pacific
Asia Pacific is likely to dominate the age-related molecular degeneration market owing to the high geriatric population and increasing disease burden in economies such as India, China, and South Korea.
Asia-Pacific is expected to deliver impressive outcomes in the global age-related molecular degeneration market. A large amount of investment, significant government meddling in the healthcare sector, and significant development in the developing economy all contribute to supporting the affordability of costly anti-VEGF products and may contribute to the market growth
Advancements in healthcare infrastructure, rising government spending on healthcare policies, and the presence of important members in Asia Pacific all contribute to the growth of the global age-related molecular degeneration market.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Category wise Insights
Based on Disease Type, Which Is the Most Prominent Segment in The Age-Related Molecular Degeneration Market?
The wet AMD Segment remains dominant among other types
The wet AMD segment dominated the market in 2023 with a revenue share of 100%. AMD accounts for more than 10-15% of macular degeneration-related vision loss cases across the globe. Lucentis, Eylea, and Beovu are the major drugs approved for the treatment of wet age-related macular degeneration. Novartis’ Beovu, a long-acting anti-VEGF, was approved by the USA FDA in October 2019. However, the unfavorable side effects of this drug, such as retinal vasculitis, will limit its broader uptake.
Dry AMD is anticipated to witness the fastest growth over the forecast period owing to the expected launch of promising product candidates by 2023 and the disease burden of dry AMD. Dry AMD accounts for 85-90% of all macular degeneration cases. The management of dry macular degeneration is currently limited to vitamin formulations. Availability of various novel therapeutic options for its treatment currently in the clinical pipeline such as Luminate, Zimura, and Intravitreal pegcetacoplan. The approval of these potential candidates may fuel the growth of the dry AMD segment in the coming years.
By Distribution Channel, which segment generates high revenue in the age-related molecular degeneration market?
Hospital Pharmacies dominated the market
The hospital pharmacy segment dominated the global market in 2023 with a revenue share of over 55.0%. The growth of the segment is attributed to the increasing prevalence of age-related macular degeneration (AMD) and hospitalization for treatment.
According to the Royal National Institute of Blind People (RNIB), around 25.3 million people were at high risk of developing age-related macular degeneration (AMD) in 2020. The majority of patients are treated by using various medications such as Lucentis, Eylea, and Beovu, which are administrated intravenously under the supervision of experienced physicians in hospitals. This growing demand for AMD treatment is anticipated to increase hospital visits, thereby driving the market.
Start-up Scenario
How do New Entrants Contribute to the Age-Related Molecular Degeneration Market?
With technological innovations happening at a rapid pace, and companies looking for ways to increase customer engagement, start-ups are taking all possible steps to establish a name for themselves in the age-related molecular degeneration market.
Some of the start-ups in the age-related molecular degeneration market include-
Makula App is an app to provides assistance for patients with age-related macular degeneration, developed by AMD Networks. The app helps the user to book an appointment, store medical data, provide medical information on AMD, mention contact person, and therapy control. The app helps ophthalmologists to manage their patient's appointments and documentation.
The Eye Machine was formed to develop, manufacture, and lease its pulsed micro-current therapy technology to medical professionals, primarily optometrists. It provides a medical device to treat macular degeneration by condensing current from direct current barriers in order to deliver energy around the eye, mitigating the effects of age-related macular degeneration and diabetic retinopathy. In 2015, an Eye machine was acquired by Acquity Medical.
Competitive Landscape
F. Hoffmann-La Roche Ltd., Novartis AG, Bayer AG, Pfizer Inc., Bausch Health Companies Inc., Regeneron Pharmaceuticals Inc., Amgen Inc., Biogen, Samsung Bioepis, Ophthotech Corporation are some of the key players in the age-related molecular degeneration industry.
The manufacturers are involved in the production of age-related molecular degeneration in a larger capacity. Research and innovation are also conducted to launch innovative products for age-related molecular degeneration.
Also, some of the key players are acquiring small pharmaceutical companies to increase their production capacity. Suppliers are focusing on expanding their market presence across the world by initiating new product launches and boosting sales. Approval for new medications and treatments for eye infections is also expected to be a major trend over the coming years.
In November 2021 - Bayer filed applications for a new therapeutic indication for aflibercept (solution for injection) in premature babies with treatment-requiring retinopathy of prematurity (ROP) in the EU and Japan.
In September 2021 - Samsung Bioepis Co., Ltd. and Biogen Inc. announced that the USA Food and Drug Administration (FDA) has approved BYOOVIZ™ (ranibizumab-nuna), a biosimilar referencing LUCENTIS® (ranibizumab) I for the treatment of neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV).
In September 2022 - Regeneron Pharmaceuticals, Inc. announced that the PHOTON trial in DME and the PULSAR trial in wAMD both demonstrated that aflibercept 8 mg 12- and 16-week dosing regimens achieved non-inferiority in vision gains compared to the EYLEA 8-week dosing regimen. In these trials, the safety of aflibercept 8 mg was consistent with the established safety profile of EYLEA. Regeneron and Bayer will submit these data to regulatory authorities in countries around the world.
Key Segments Covered in the Age-Related Molecular Degeneration Market Industry Survey
Age-Related Molecular Degeneration Market by Product Type:
Eylea
Lucentis
Beovu
Others
Age-Related Molecular Degeneration Market by Disease Type:
Dry AMD
Wet AMD
Age-Related Molecular Degeneration Market by Distribution Channel:
Hospital Pharmacy
Specialty Pharmacy
Online Pharmacy
Age-Related Molecular Degeneration Market by Region:
North AmericaAge-Related Molecular Degeneration Market
Latin America Age-Related Molecular Degeneration Market
Europe Age-Related Molecular Degeneration Market
South Asia & Pacific Age-Related Molecular Degeneration Market
East Asia Age-Related Molecular Degeneration Market
MEA Age-Related Molecular Degeneration Market
Frequently Asked Questions
What is the expected valuation of the age related molecular degeneration market?
The global age-related molecular degeneration market is likely to reach a valuation of US$ 11.28 Million by the end of 2023.
Who are the key players in the age related molecular degeneration market?
F. Hoffmann-La Roche Ltd., Novartis AG, Bayer AG, Pfizer Inc., Bausch Health Companies Inc., Regeneron Pharmaceuticals Inc. are some of the key players in the global age related molecular degeneration market
What are the future prospects for age related molecular degeneration market sales?
Sales of the age-related molecular degeneration market are likely to expand at 7% CAGR through 2033.
Which are the top 5 countries driving demand for biopharma plastics?
The USA, Canada, Japan, China, & Germany are expected to drive most of the demand for the age-related molecular degeneration market.
What will be the global age related molecular degeneration market revenue total by 2033?
By the end of 2033, the global market for age-related molecular degeneration market is predicted to reach a valuation of US$22.19Million
Table of Content
1. Executive Summary | Age-Related Molecular Degeneration Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Product, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Product, 2023 to 2033
5.3.1. Eylea
5.3.2. Lucentis
5.3.3. Beovu
5.3.4. Others
5.4. Y-o-Y Growth Trend Analysis By Product, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Product, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Disease Type
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Disease Type, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Disease Type, 2023 to 2033
6.3.1. Dry AMD
6.3.2. Wet AMD
6.4. Y-o-Y Growth Trend Analysis By Disease Type, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Disease Type, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033
7.3.1. Hospital Pharmacy
7.3.2. Specialty Pharmacy
7.3.3. Online Pharmacy
7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. South Asia & Pacific
8.3.5. East Asia
8.3.6. Middle East and Africa (MEA)
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. United States of America
9.2.1.2. Canada
9.2.2. By Product
9.2.3. By Disease Type
9.2.4. By Distribution Channel
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Product
9.3.3. By Disease Type
9.3.4. By Distribution Channel
9.4. Key Takeaways
10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Product
10.2.3. By Disease Type
10.2.4. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Product
10.3.3. By Disease Type
10.3.4. By Distribution Channel
10.4. Key Takeaways
11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. United Kingdom
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Europe
11.2.2. By Product
11.2.3. By Disease Type
11.2.4. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Product
11.3.3. By Disease Type
11.3.4. By Distribution Channel
11.4. Key Takeaways
12. South Asia & Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Malaysia
12.2.1.3. Singapore
12.2.1.4. Thailand
12.2.1.5. Australia
12.2.1.6. New Zealand
12.2.1.7. Rest of South Asia & Pacific
12.2.2. By Product
12.2.3. By Disease Type
12.2.4. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Product
12.3.3. By Disease Type
12.3.4. By Distribution Channel
12.4. Key Takeaways
13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.2. By Product
13.2.3. By Disease Type
13.2.4. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Product
13.3.3. By Disease Type
13.3.4. By Distribution Channel
13.4. Key Takeaways
14. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. GCC Countries
14.2.1.2. South Africa
14.2.1.3. Israel
14.2.1.4. Rest of MEA
14.2.2. By Product
14.2.3. By Disease Type
14.2.4. By Distribution Channel
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Product
14.3.3. By Disease Type
14.3.4. By Distribution Channel
14.4. Key Takeaways
15. Key Countries Market Analysis
15.1. United States of America
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2022
15.1.2.1. By Product
15.1.2.2. By Disease Type
15.1.2.3. By Distribution Channel
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2022
15.2.2.1. By Product
15.2.2.2. By Disease Type
15.2.2.3. By Distribution Channel
15.3. Brazil
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2022
15.3.2.1. By Product
15.3.2.2. By Disease Type
15.3.2.3. By Distribution Channel
15.4. Mexico
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2022
15.4.2.1. By Product
15.4.2.2. By Disease Type
15.4.2.3. By Distribution Channel
15.5. Germany
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2022
15.5.2.1. By Product
15.5.2.2. By Disease Type
15.5.2.3. By Distribution Channel
15.6. United Kingdom
15.6.1. Pricing Analysis
15.6.2. Market Share Analysis, 2022
15.6.2.1. By Product
15.6.2.2. By Disease Type
15.6.2.3. By Distribution Channel
15.7. France
15.7.1. Pricing Analysis
15.7.2. Market Share Analysis, 2022
15.7.2.1. By Product
15.7.2.2. By Disease Type
15.7.2.3. By Distribution Channel
15.8. Spain
15.8.1. Pricing Analysis
15.8.2. Market Share Analysis, 2022
15.8.2.1. By Product
15.8.2.2. By Disease Type
15.8.2.3. By Distribution Channel
15.9. Italy
15.9.1. Pricing Analysis
15.9.2. Market Share Analysis, 2022
15.9.2.1. By Product
15.9.2.2. By Disease Type
15.9.2.3. By Distribution Channel
15.10. India
15.10.1. Pricing Analysis
15.10.2. Market Share Analysis, 2022
15.10.2.1. By Product
15.10.2.2. By Disease Type
15.10.2.3. By Distribution Channel
15.11. Malaysia
15.11.1. Pricing Analysis
15.11.2. Market Share Analysis, 2022
15.11.2.1. By Product
15.11.2.2. By Disease Type
15.11.2.3. By Distribution Channel
15.12. Singapore
15.12.1. Pricing Analysis
15.12.2. Market Share Analysis, 2022
15.12.2.1. By Product
15.12.2.2. By Disease Type
15.12.2.3. By Distribution Channel
15.13. Thailand
15.13.1. Pricing Analysis
15.13.2. Market Share Analysis, 2022
15.13.2.1. By Product
15.13.2.2. By Disease Type
15.13.2.3. By Distribution Channel
15.14. Australia
15.14.1. Pricing Analysis
15.14.2. Market Share Analysis, 2022
15.14.2.1. By Product
15.14.2.2. By Disease Type
15.14.2.3. By Distribution Channel
15.15. New Zealand
15.15.1. Pricing Analysis
15.15.2. Market Share Analysis, 2022
15.15.2.1. By Product
15.15.2.2. By Disease Type
15.15.2.3. By Distribution Channel
15.16. China
15.16.1. Pricing Analysis
15.16.2. Market Share Analysis, 2022
15.16.2.1. By Product
15.16.2.2. By Disease Type
15.16.2.3. By Distribution Channel
15.17. Japan
15.17.1. Pricing Analysis
15.17.2. Market Share Analysis, 2022
15.17.2.1. By Product
15.17.2.2. By Disease Type
15.17.2.3. By Distribution Channel
15.18. South Korea
15.18.1. Pricing Analysis
15.18.2. Market Share Analysis, 2022
15.18.2.1. By Product
15.18.2.2. By Disease Type
15.18.2.3. By Distribution Channel
15.19. GCC Countries
15.19.1. Pricing Analysis
15.19.2. Market Share Analysis, 2022
15.19.2.1. By Product
15.19.2.2. By Disease Type
15.19.2.3. By Distribution Channel
15.20. South Africa
15.20.1. Pricing Analysis
15.20.2. Market Share Analysis, 2022
15.20.2.1. By Product
15.20.2.2. By Disease Type
15.20.2.3. By Distribution Channel
15.21. Israel
15.21.1. Pricing Analysis
15.21.2. Market Share Analysis, 2022
15.21.2.1. By Product
15.21.2.2. By Disease Type
15.21.2.3. By Distribution Channel
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. By Regional
16.3.2. By Product
16.3.3. By Disease Type
16.3.4. By Distribution Channel
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. F. Hoffmann-La Roche Ltd.
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.2. Novartis AG
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.3. Bayer AG
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.4. Pfizer Inc.
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.5. Bausch Health Companies Inc.
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.6. Regeneron Pharmaceuticals Inc.
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.7. Amgen Inc.
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.8. Biogen
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.9. Samsung Bioepis
17.1.9.1. Overview
17.1.9.2. Product Portfolio
17.1.9.3. Profitability by Market Segments
17.1.9.4. Sales Footprint
17.1.9.5. Strategy Overview
17.1.9.5.1. Marketing Strategy
17.1.10. Ophthotech Corporation
17.1.10.1. Overview
17.1.10.2. Product Portfolio
17.1.10.3. Profitability by Market Segments
17.1.10.4. Sales Footprint
17.1.10.5. Strategy Overview
17.1.10.5.1. Marketing Strategy
18. Assumptions & Acronyms Used19. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033
Table 2: Global Market Value (US$ Million) Forecast by Product, 2018 to 2033
Table 3: Global Market Value (US$ Million) Forecast by Disease Type, 2018 to 2033
Table 4: Global Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 5: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 6: North America Market Value (US$ Million) Forecast by Product, 2018 to 2033
Table 7: North America Market Value (US$ Million) Forecast by Disease Type, 2018 to 2033
Table 8: North America Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 10: Latin America Market Value (US$ Million) Forecast by Product, 2018 to 2033
Table 11: Latin America Market Value (US$ Million) Forecast by Disease Type, 2018 to 2033
Table 12: Latin America Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 13: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 14: Europe Market Value (US$ Million) Forecast by Product, 2018 to 2033
Table 15: Europe Market Value (US$ Million) Forecast by Disease Type, 2018 to 2033
Table 16: Europe Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 17: South Asia & Pacific Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 18: South Asia & Pacific Market Value (US$ Million) Forecast by Product, 2018 to 2033
Table 19: South Asia & Pacific Market Value (US$ Million) Forecast by Disease Type, 2018 to 2033
Table 20: South Asia & Pacific Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 21: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 22: East Asia Market Value (US$ Million) Forecast by Product, 2018 to 2033
Table 23: East Asia Market Value (US$ Million) Forecast by Disease Type, 2018 to 2033
Table 24: East Asia Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 25: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 26: MEA Market Value (US$ Million) Forecast by Product, 2018 to 2033
Table 27: MEA Market Value (US$ Million) Forecast by Disease Type, 2018 to 2033
Table 28: MEA Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
List of Charts
Figure 1: Global Market Value (US$ Million) by Product, 2023 to 2033
Figure 2: Global Market Value (US$ Million) by Disease Type, 2023 to 2033
Figure 3: Global Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 4: Global Market Value (US$ Million) by Region, 2023 to 2033
Figure 5: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033
Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 8: Global Market Value (US$ Million) Analysis by Product, 2018 to 2033
Figure 9: Global Market Value Share (%) and BPS Analysis by Product, 2023 to 2033
Figure 10: Global Market Y-o-Y Growth (%) Projections by Product, 2023 to 2033
Figure 11: Global Market Value (US$ Million) Analysis by Disease Type, 2018 to 2033
Figure 12: Global Market Value Share (%) and BPS Analysis by Disease Type, 2023 to 2033
Figure 13: Global Market Y-o-Y Growth (%) Projections by Disease Type, 2023 to 2033
Figure 14: Global Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 15: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 16: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 17: Global Market Attractiveness by Product, 2023 to 2033
Figure 18: Global Market Attractiveness by Disease Type, 2023 to 2033
Figure 19: Global Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 20: Global Market Attractiveness by Region, 2023 to 2033
Figure 21: North America Market Value (US$ Million) by Product, 2023 to 2033
Figure 22: North America Market Value (US$ Million) by Disease Type, 2023 to 2033
Figure 23: North America Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 24: North America Market Value (US$ Million) by Country, 2023 to 2033
Figure 25: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 28: North America Market Value (US$ Million) Analysis by Product, 2018 to 2033
Figure 29: North America Market Value Share (%) and BPS Analysis by Product, 2023 to 2033
Figure 30: North America Market Y-o-Y Growth (%) Projections by Product, 2023 to 2033
Figure 31: North America Market Value (US$ Million) Analysis by Disease Type, 2018 to 2033
Figure 32: North America Market Value Share (%) and BPS Analysis by Disease Type, 2023 to 2033
Figure 33: North America Market Y-o-Y Growth (%) Projections by Disease Type, 2023 to 2033
Figure 34: North America Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 35: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 36: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 37: North America Market Attractiveness by Product, 2023 to 2033
Figure 38: North America Market Attractiveness by Disease Type, 2023 to 2033
Figure 39: North America Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 40: North America Market Attractiveness by Country, 2023 to 2033
Figure 41: Latin America Market Value (US$ Million) by Product, 2023 to 2033
Figure 42: Latin America Market Value (US$ Million) by Disease Type, 2023 to 2033
Figure 43: Latin America Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 44: Latin America Market Value (US$ Million) by Country, 2023 to 2033
Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 48: Latin America Market Value (US$ Million) Analysis by Product, 2018 to 2033
Figure 49: Latin America Market Value Share (%) and BPS Analysis by Product, 2023 to 2033
Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Product, 2023 to 2033
Figure 51: Latin America Market Value (US$ Million) Analysis by Disease Type, 2018 to 2033
Figure 52: Latin America Market Value Share (%) and BPS Analysis by Disease Type, 2023 to 2033
Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Disease Type, 2023 to 2033
Figure 54: Latin America Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 55: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 56: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 57: Latin America Market Attractiveness by Product, 2023 to 2033
Figure 58: Latin America Market Attractiveness by Disease Type, 2023 to 2033
Figure 59: Latin America Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 60: Latin America Market Attractiveness by Country, 2023 to 2033
Figure 61: Europe Market Value (US$ Million) by Product, 2023 to 2033
Figure 62: Europe Market Value (US$ Million) by Disease Type, 2023 to 2033
Figure 63: Europe Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 64: Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 65: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 68: Europe Market Value (US$ Million) Analysis by Product, 2018 to 2033
Figure 69: Europe Market Value Share (%) and BPS Analysis by Product, 2023 to 2033
Figure 70: Europe Market Y-o-Y Growth (%) Projections by Product, 2023 to 2033
Figure 71: Europe Market Value (US$ Million) Analysis by Disease Type, 2018 to 2033
Figure 72: Europe Market Value Share (%) and BPS Analysis by Disease Type, 2023 to 2033
Figure 73: Europe Market Y-o-Y Growth (%) Projections by Disease Type, 2023 to 2033
Figure 74: Europe Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 75: Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 76: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 77: Europe Market Attractiveness by Product, 2023 to 2033
Figure 78: Europe Market Attractiveness by Disease Type, 2023 to 2033
Figure 79: Europe Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 80: Europe Market Attractiveness by Country, 2023 to 2033
Figure 81: South Asia & Pacific Market Value (US$ Million) by Product, 2023 to 2033
Figure 82: South Asia & Pacific Market Value (US$ Million) by Disease Type, 2023 to 2033
Figure 83: South Asia & Pacific Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 84: South Asia & Pacific Market Value (US$ Million) by Country, 2023 to 2033
Figure 85: South Asia & Pacific Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 86: South Asia & Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 87: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 88: South Asia & Pacific Market Value (US$ Million) Analysis by Product, 2018 to 2033
Figure 89: South Asia & Pacific Market Value Share (%) and BPS Analysis by Product, 2023 to 2033
Figure 90: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Product, 2023 to 2033
Figure 91: South Asia & Pacific Market Value (US$ Million) Analysis by Disease Type, 2018 to 2033
Figure 92: South Asia & Pacific Market Value Share (%) and BPS Analysis by Disease Type, 2023 to 2033
Figure 93: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Disease Type, 2023 to 2033
Figure 94: South Asia & Pacific Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 95: South Asia & Pacific Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 96: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 97: South Asia & Pacific Market Attractiveness by Product, 2023 to 2033
Figure 98: South Asia & Pacific Market Attractiveness by Disease Type, 2023 to 2033
Figure 99: South Asia & Pacific Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 100: South Asia & Pacific Market Attractiveness by Country, 2023 to 2033
Figure 101: East Asia Market Value (US$ Million) by Product, 2023 to 2033
Figure 102: East Asia Market Value (US$ Million) by Disease Type, 2023 to 2033
Figure 103: East Asia Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 104: East Asia Market Value (US$ Million) by Country, 2023 to 2033
Figure 105: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 106: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 107: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 108: East Asia Market Value (US$ Million) Analysis by Product, 2018 to 2033
Figure 109: East Asia Market Value Share (%) and BPS Analysis by Product, 2023 to 2033
Figure 110: East Asia Market Y-o-Y Growth (%) Projections by Product, 2023 to 2033
Figure 111: East Asia Market Value (US$ Million) Analysis by Disease Type, 2018 to 2033
Figure 112: East Asia Market Value Share (%) and BPS Analysis by Disease Type, 2023 to 2033
Figure 113: East Asia Market Y-o-Y Growth (%) Projections by Disease Type, 2023 to 2033
Figure 114: East Asia Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 115: East Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 116: East Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 117: East Asia Market Attractiveness by Product, 2023 to 2033
Figure 118: East Asia Market Attractiveness by Disease Type, 2023 to 2033
Figure 119: East Asia Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 120: East Asia Market Attractiveness by Country, 2023 to 2033
Figure 121: MEA Market Value (US$ Million) by Product, 2023 to 2033
Figure 122: MEA Market Value (US$ Million) by Disease Type, 2023 to 2033
Figure 123: MEA Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 124: MEA Market Value (US$ Million) by Country, 2023 to 2033
Figure 125: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 126: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 127: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 128: MEA Market Value (US$ Million) Analysis by Product, 2018 to 2033
Figure 129: MEA Market Value Share (%) and BPS Analysis by Product, 2023 to 2033
Figure 130: MEA Market Y-o-Y Growth (%) Projections by Product, 2023 to 2033
Figure 131: MEA Market Value (US$ Million) Analysis by Disease Type, 2018 to 2033
Figure 132: MEA Market Value Share (%) and BPS Analysis by Disease Type, 2023 to 2033
Figure 133: MEA Market Y-o-Y Growth (%) Projections by Disease Type, 2023 to 2033
Figure 134: MEA Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 135: MEA Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 136: MEA Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 137: MEA Market Attractiveness by Product, 2023 to 2033
Figure 138: MEA Market Attractiveness by Disease Type, 2023 to 2033
Figure 139: MEA Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 140: MEA Market Attractiveness by Country, 2023 to 2033
